Strong growth, margin drag from strategic investments
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Q1 revenue growth of 25.7% corroborates guidance; PAT growth 12.2% aligns. However, QoQ PAT declined 14.5% due to investments—not flagged on call.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 shows strong revenue momentum (26% YoY) with broad-based growth and a mid-tier FY27 guidance upgrade, but near-term profit growth is constrained by strategic investments (R&D 9% of revenue, US branded drag 150 bps). India branded underperformance (7% vs 10%+ market growth) and temporary Bosutinib contribution (1 month in Q1, exclusivity ends Nov) are key near-term risks.
₹2150 Cr
Revenue · +25.7% YoY₹173 Cr
Reported PAT · +12.2% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue grew 26% YoY supported by all segments
METDelivered 25.7% YoY revenue growth; broad-based across India (7%), International Generics (37%), API (33%)
EBITDA margin at 16% with 21% YoY growth
METEBITDA ₹348 Cr / ₹2150 Cr revenue = 16.2% margin; consistent with delivery
PAT grew 12% YoY to ₹173 Cr despite US branded drag
METDelivered PAT ₹172.4 Cr with 12.2% YoY growth; QoQ PAT fell 14.5% (not disclosed on call)
US Generics grew 49% YoY, ex-Bosutinib ~25% from new launches
METIf reported 49% includes only 1 month of Bosutinib (June launch), base growth ~25% is plausible; consistent with 6-7 launches in Q1
Upgraded FY27 growth guidance to mid-teen range from low double-digit
METPrior guidance stated low double-digit; new guidance mid-teens if US Generics mid-to-high teens realized; explicit upgrade
Earnings quality
What changed since the last call
FY27 revenue growth upgraded
UpgradePrior: low double-digit (~10-11%); Now: mid-teen (~15%); driven by US Generics outperformance (low-mid-teens → mid-high-teens)
US Generics guidance raised
UpgradePrior: low to mid-teens; Now: mid to high-teens; Q1 delivered 49% YoY (37% ex-Bosutinib), Bosutinib + 15 more launches planned
India business guidance downgraded
DowngradeNow expected at high single-digit growth (vs prior implied double-digit); management acknowledged 7% Q1 vs market 10%+
API guidance maintained but softened
NeutralPrior: grow ~10% plus/minus; Q1 delivered 33%; Now: 'above 10% level' end of year; guidance lowered from Q1 momentum
EBITDA margin guidance maintained
MaintainedCore margins high-teens, offset by 150 bps US branded drag, consolidated ~16-17%; 150 bps dilution as previously guided
The Q&A
Analysts pressed hard on margin trajectory vs FY26 (concerns about QoQ margin compression, Bosutinib benefit offset). Management held firm on high-teens core margin claim but acknowledged gross margin headwinds (forex, mix, maintenance). On India underperformance, management was candid (7% vs market) but vague on turnaround timing (1-2 quarters). On Bosutinib post-exclusivity, MD explicitly dodged, saying 'can't really foresee' and 'depends on competition.'
Bosutinib exclusivity mechanics — Damayanti Kerai, HSBC
AnsweredConfirmed exclusivity on 100mg, 500mg. Ex-Bosutinib, US grew ~25%, driven by 6-7 new launches in Q1 + some Q4 launches.
US branded profitability timeline — Damayanti Kerai, HSBC
AnsweredSoft launch. Expect positive contribution next financial year onwards. J-curve trajectory: Q1-Q2 heavy investment, sales ramp Q3-Q4, breakeven trend by year-end.
US base business sustainability — Chirag, DSP Mutual Funds
PartialWould like it to be new normal, but have to balance with price erosion. At least next 1-2 quarters should continue this trend.
Bosutinib post-exclusivity sustainability — Chirag, DSP Mutual Funds
DodgedTough to say. Exclusivity till November, you'll see Q2 and part of Q3 sales. Over that, if competition enters, will be drastic because volumes very small. Can't really foresee beyond.
Gross margin pressure — Chirag, DSP Mutual Funds
AnsweredSimilar Q-o-Q. Guided 70-75% range, sits well within. Factors: Middle East solvent prices up, product mix, debottlenecking maintenance shutdown on Ophthaline (capacity expanded without capex).
Animal Health growth sustainability — Chirag, DSP Mutual Funds
PartialCombination of portfolio expansion (farm animals, poultry) and field force productivity. Expect to continue momentum on existing portfolio expansion and operational efficiency.
India branded turnaround timeline — Rahul Jeewani, IIFL Securities
PartialWill take couple of quarters, work in progress. Going grassroots to territories. Expect positive trends in another quarter or 2.
Acute segment recovery — Rahul Jeewani, IIFL Securities
PartialTrajectory improving, especially Azithral and cough/cold portfolio; traction building.
EBITDA margin guidance clarity — Rahul Jeewani, IIFL Securities
PartialGross margins a bit diluted in first half vs last year. Depends on US branded ramp-up whether breakeven Q4 or next year Q1. May be few percentage points and quarters here or there.
API segment guidance softening — Rashmi Shetty, Dolat Capital
PartialQ1 healthy. At end of year, will be above 10% level. Continue growing next couple quarters.
India business FY27 guidance — Rashmi Shetty, Dolat Capital
AnsweredHigh single-digit growth. Will bridge the gap vs market. Aligned to market this year.
US Generics post-Bosutinib — Rashmi Shetty, Dolat Capital
PartialKey is meaningful launches. Have decent pipeline. Even ex-Bosutinib, 15 more launches planned for rest of year, similar number next year. New launches offset erosion, plus branded contribute.
Chronic portfolio in India — Foram Parekh, Bank of Baroda
PartialSpecialty ~60% of India revenue. Aligned to market on Gynae, Gastro, Ophthal. Driving via quality prescriptions, prescriber consolidation, field productivity.
FY28 margin outlook — Foram Parekh, Bank of Baroda
PartialWill guide for FY28 when we get there. Directionally, operating leverage in core will play out. US branded expected to scale up and contribute to profit, expanding overall margin.
Depreciation and intangibles spike — Chirag, DSP Mutual Funds
AnsweredIntangible assets acquired for US branded expansion (product acquisition). Amortized over 7-8 years. Capitalized in Q4, so higher year-on-year. Also added ₹400 Cr capex.
Interest cost and debt trajectory — Rashmi Shetty, Dolat Capital
AnsweredGross debt ~₹1600 Cr (vs March higher due to higher receivables from sales). Combination of higher debt but lower rates. Working capital should optimize as receivables unwind. Expect to return to March levels minimum and scale down further to 1x EBITDA.
Guidance
FY27 consolidated: mid-teen growth (upgraded from low double-digit)
MediumUpgraded based on Q1 US Generics momentum + 15 more launches planned for rest of year; subject to normal market conditions
FY27 US Generics: mid-to-high-teens growth (upgraded from low-to-mid-teens)
MediumQ1 delivered 49% YoY (37% ex-Bosutinib); Bosutinib exclusivity ends Nov; pipeline visibility for 15+ launches rest of year
FY27 India branded: high single-digit growth (aligned to market)
LowCurrently 7% vs market 10%+; new sales head Ramesh Juneja; turnaround expected 1-2 quarters; gap-bridging initiative
FY27 API: above 10% level (softened from Q1 33% achievement)
MediumQ1 strong; full-year guidance 'above 10%' is vague; likely 10-15% range based on trajectory
FY27 ROW (ex-US): ~15% growth (consistent with prior years, targeting mid-teens)
MediumHistorically grown ~20%; management conservative ('100% achievable'); quarterly variance expected (B2B business)
Core EBITDA margins: high-teens (improved from mid-teens FY26)
MediumOperating leverage on higher volumes + capex benefits; Q1 EBITDA margin 16% supports this trajectory
Consolidated EBITDA margins: high-teens offset by 150 bps US branded drag = net ~16-17%
MediumUS branded margin dilution guided 100-150 bps for full year; Q1 impact higher than full-year average (ramp-up phase)
Gross margins: 70-75% range (maintained)
MediumQ1 within range despite mix headwind, forex, maintenance shutdown; expected to improve as utilization increases
Continued investment in manufacturing debottlenecking + capacity expansion
HighAdded ₹400 Cr capex last year; Ophthaline facility maintenance completed; strategic capex allocation maintained
Risks the call surfaced
Bosutinib post-exclusivity
HighBosutinib 180-day exclusivity ends Nov 2026. Only 1 month of sales in Q1. Small-indication product with good pricing but uncertain post-exclusivity sustainability. MD said 'can't really foresee' and '2-player market until Nov'.
India branded market share loss
HighIndia branded at 7% growth vs market ~10-11%. Underperformance in acute segment acknowledged. New sales head Ramesh Juneja hired to drive turnaround, but timing uncertain (1-2 quarters). If turnaround delays, India business could drag consolidated growth.
Gross margin compression
MediumQ1 gross margins flattish QoQ despite Bosutinib launch. Solvent prices up (Middle East issues), product mix headwind, debottlenecking maintenance on Ophthaline. Within 70-75% guided range but directional pressure.
US branded Pivya profitability timing
MediumUS branded Pivya in soft-launch phase Q1. Expected margin drag 150 bps full year. Profitability only expected next FY. If ramp-up slower than expected, margin impact could extend or deepen.
Working capital and interest cost
LowGross debt increased to ₹1600 Cr (vs March) due to higher receivables from strong sales. Interest cost up. Receivables expected to unwind Q2-Q3, but timing uncertain.
Management
Score 7/10. Direct on most topics; candid on challenges (India lag, Bosutinib uncertainty). Some hedging on long-term guidance (post-exclusivity, FY28 margins). CFO occasionally deferred detail ('we can touch base'). Strong Q1 delivery (26% YoY revenue, 21% EBITDA growth) corroborates execution narrative. However, QoQ PAT declined 14.5% due to heavy R&D/Pivya investment — not flagged upfront; strategic but concerning.
1 · Q2-Q4 FY27
15+ additional product launches planned for US Generics
2 · Q2-Q4 FY27
US Branded Pivya ramp towards breakeven by year-end
3 · Nov 2026
Bosutinib 180-day exclusivity ends; competitive entry likely
India branded underperformance (7% vs 10%+ market growth) and temporary Bosutinib contribution (1 month in Q1, exclusivity ends Nov) are key near-term risks.
US specialty ramp under way—watch ANDA momentum & margin durability
Alembic reports Q1 FY27 tomorrow; the real story is how fast its pivot to US generics and oncology is paying off, and whether the Warning Letter signals deeper inspection risk.
The setup: specialty pivot picking up steam
Alembic is mid-pivot: away from commoditized oral generics (margin-eroding) toward high-complexity specialty and oncology generics, where pricing is stickier and scale comes from volume discipline, not unit multiples. Q1 FY27 lands at the inflection point—cumulative ANDA approvals now 235 (217 final), but the real watch is how many specialty/oncology approvals ramp contribution and defend gross margin. Street consensus is Buy at ₹1,015 (upside from ₹805), betting on execution of this shift. The risk: announced 15–20 ANDA launches for FY27, but pipeline concentration risk (if delayed oncology approvals slip into Q2/Q3, margins stay under pressure this quarter).
~₹350–360 Cr
On-run from FY26 base; US generics mix-shift neutral to slightly up
~60–62%
Specialty launches should begin offsetting oral-solids erosion by Q2
~28–30%
Operating leverage steady if mix turns as planned
~38–40%
FY26 base; this quarter likely flat/up low-single-digit as launches ramp
A strong print means: specialty/oncology approvals begin lifting US revenue % above prior-run; gross margin holds steady or ticks up; US business (exclusive of Pivya brand launch) shows 5%+ organic growth. Alembic would also flag the Canadian JV (Difgen minority stake, announced Jun 6) and any first-half branded-product traction. A weak print looks like: specialty approvals cluster in Q2, so Q1 US generic mix shift is muted; gross margin contracts 100+ bps on commoditized volume; US growth <2%; Warning Letter update reveals pipeline pause risk.
On track? The FY27 guidance backdrop
FY26 (ended Mar 31, 2026) full-year guidance unverified in our DB—but Street's current forecast is ₹7,410 Cr revenue (+~8% from prior run) and EPS growth 23% to ₹36.43, implying margin expansion and/or improved capital efficiency. Q1 FY27 will set the tone: if specialty ramp is pacing toward the 15–20 full-year target, Street's buy case (pivot narrative + compounding EPS) gains conviction. If the first quarter is pulled back by Warning Letter fallout or delayed approvals, the FY27 target becomes a 3-quarter sprint, raising execution risk.
Since last quarter: the filings scan
1 · USFDA approvals surge—specialty/oncology track gaining
Prucalopride Tablets (1/2 mg, Jul 28) — GI motility generic, immediate-care use case. Dapsone Gel 5% (Jun 26) — dermatology, acne. Oseltamivir Phosphate oral suspension (Jun 26) — antivirals. Tretinoin Cream 0.05% (Jun 12) — derma/retinoids. Haloperidol Tablets (Jun 5) — psychiatry. All final approvals. Plus tentative approvals for Binimetinib Tablets 45 mg (Jun 19) ($260M market, oncology) and Larotrectinib Capsules 25/100 mg (Jun 11) ($91M market, oncology)—these are on the specialty roadmap and should ramp contribution in H2.
2 · Warning Letter to Clinical Investigator—inspection risk flag
Jul 13: USFDA issued Warning Letter to a Clinical Investigator at Alembic's Vadodara bioequivalence facility (dated Jul 10). This is not a direct facility warning but signals USFDA scrutiny of BE study integrity/conduct. Doesn't invalidate prior approvals but may tighten submission timelines or trigger additional audits. Market read: raises inspection risk; watch for update on pipeline pauses or submission delays.
3 · Canadian JV—optionality, not material near-term
Jun 6: Shareholders' Agreement signed for minority stake in Canadian pharmaceutical JV (17989377 Canada Inc.) with Difgen Holdings and Sukhad Juneja. No dollar amount disclosed. Frames as strategic optionality in North America; probably not a Q1 earnings driver but signals inorganic appetite.
4 · Management continuity: Tushar Mehta (Head-R&D API) joins
Jun 3: Appointed Tushar Mehta as Head-R&D (API), 24+ years API R&D experience. Also Sujit Bhayani as Independent Director (Jun 18). Routine management refresh; no material strategy signal.
5 · Dividend record date (Jul 29); AGM/Board meetings imminent
FY26 dividend record date Jul 29, 2026. Board convenes Aug 4 to approve Q1 results. AGM Aug 5 (notice filed). No guidance revision in disclosures reviewed; assume FY27 road-map stands.
Price & momentum going in
Stock at ₹805 (as of Aug 3), down 19% from 52-week high ₹998 but up 26% off the low ₹636. Trading below SMA20 (₹820) but above SMA50 (₹785) and SMA200 (₹799)—technical neutral. RSI 45.2 (mid-range). Volume trend normal. Ownership stable: FII 4.25% (near 4-year lows), DII 16.18% (steady), promoter 69.74% (locked). No recent pledges or insider action flagged. Street consensus at ₹1,015 suggests 26% upside if execution (specialty ramp, margin recovery) validates.
The three things to watch on result day
1. US revenue & specialty mix: Will Q1 US organic growth show first signs of specialty lift (5%+ growth), or is the ramp still loading in Q2? Gross margin clue: if specialty launches are stuck in approvals, gross margin will contract 50–100 bps this quarter.
2. Warning Letter follow-up & pipeline commentary: Any mention of facility audit, submission delays, or pipeline pauses? This is the one near-term execution risk that Street isn't heavily pricing. If the company signals Q2/Q3 delays, expect downgrades.
3. Full-year guidance reaffirmation: Is the 15–20 ANDA launch target for FY27 still on? Are Binimetinib, Larotrectinib (oncology tentatives) on track for final approval/launch in H2? Investors will want confirmation the specialty pivot is on schedule.
Alembic Q1FY27 revenue up 26% YoY beats guidance; US ramp drags consol PAT growth to 12%
PAT +12.19% YoY · revenue +25.67% · margins compressing
₹2,149.77 Cr
+25.67% YoY
₹172.36 Cr
+12.19% YoY
7.96%
-1pp YoY
₹8.8
Alembic Pharmaceuticals' consolidated revenue for Q1 FY27 rose 25.7% YoY to ₹2,149.77 Cr (from ₹1,710.72 Cr) and 16.4% QoQ, comfortably ahead of management's own low-double-digit FY27 topline growth target set on the May 2026 concall. Consolidated PAT (before non-controlling interests) was ₹172.36 Cr, up 12.2% YoY but down 14.5% QoQ from ₹201.54 Cr; EPS was ₹8.80 versus ₹7.85 a year ago. There were no exceptional items this quarter or a year ago, so the YoY PAT comparison is clean — the gap versus revenue growth is a margin story, not a one-off.
Q1 FY-2027 vs prior quarters
Consolidated net profit margin compressed to 8.05% from 9.02% a year ago, and operating margin eased to 16.18% from 16.84%, consistent with the 100-150bps EBITDA drag management flagged from scaling up the US branded business. The QoQ decline also overstates weakness: Q4FY26's ₹201.54 Cr PAT was lifted by a one-off ₹114.21 Cr deferred-tax credit that did not recur this quarter. Standalone tells a starkly different story — standalone PAT jumped 90.3% YoY to ₹196.96 Cr (from ₹103.52 Cr), EPS ₹10.02 versus ₹5.27. The gap between standalone (+90% PAT) and consolidated (+12% PAT) growth points to a subsidiary drag: the auditor's report flags one unreviewed subsidiary posting a ₹25.93 Cr net loss this quarter, consistent with the costs of the US ramp management has been guiding to.
The stock went into the print at ₹812.1, down 3% over the past month of trading.
For context: revenue is at a 6-quarter high.
Alembic Pharmaceuticals is targeting low double-digit consolidated top-line growth for FY27, driven by continued momentum in international generics (low to mid-teen growth) and API businesses (high single to low double-digit growth). The company expects the U.S. branded business to scale significantly, supported by sel
— This quarter: beat
No specific Q1 FY27 consensus revenue/PAT figures turned up in search; the pre-result preview's expectation of ~₹350-360 Cr revenue and 28-30% EBITDA margin sits far below the scale of the reported numbers (₹2,149.77 Cr consolidated revenue, 16.18% OPM), suggesting that estimate referenced a sub-segment (likely the US business) rather than total company revenue — this filing discloses only one reportable segment, so a like-for-like check isn't possible. Pipeline momentum flagged pre-result continued: final USFDA approval for Prucalopride Tablets (Jul 28) and partner Natco Pharma's tentative USFDA approval for Olaparib Tablets (Jul 18). The inspection-risk flag also materialised — USFDA issued a Warning Letter to a clinical investigator (Jul 13) — though this filing gives no detail on scope or remediation. The Board separately fixed Jul 29 as the FY26 dividend record date and set the 16th AGM for Aug 5, both administrative and unrelated to this quarter's numbers. Management has not published a press-release commentary on this result in our records.
W1
Consolidated OPM (currently 16.18%) versus management's 2-3 year path back to ~20% EBITDA margins as the US branded ramp (100-150bps guided drag) plays out
W2
Resolution/scope of the USFDA Warning Letter to a clinical investigator (issued Jul 13) — watch for inspection escalation or product-specific fallout in Q2
W3
Whether the loss-making subsidiary (₹25.93 Cr net loss this quarter) narrows — the key swing factor between standalone (+90% PAT YoY) and consolidated (+12% PAT YoY) growth